Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the Merger is not consummated by December 28, 2026, which period may be extended automatically for two t